RUNX1T1 and neoplasm: However, triple combination therapy with MAPKi, ETO, and dichloroacetate (DCA; a pyruvate dehydrogenase kinase inhibitor that forces glycolytic flux into mitochondria), remarkably delayed tumor relapse in A375P xenografts [59].